Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000244934

Medchemexpress LLC Regorafenib monohydrate | 1019206-88-2 | MFCD17170366 | 99.9% | 500.8 g/mol | C21H17ClF4N4O4 | 50 MG
SDP

Catalog No. 5000244934
Encompass_Preferred

Regorafenib monohydrate is the monohydrate form of regorafenib, a multi-targeted receptor tyrosine kinase inhibitor used as a research reagent and analytical standard. It exhibits potent inhibition of VEGFR, PDGFR, KIT, RET, and RAF kinases and is used in preclinical assays to study antitumor and antiangiogenic activity.

  • High purity (≈99.9%) suitable for analytical work.
  • Monohydrate form with molecular weight 500.8 g/mol.
  • Useful as an analytical standard and research reagent in kinase assays.
  • Available in small, quantified laboratory packages for preclinical studies.

Catalog No. 50-002-44934 Supplier Medchemexpress LLC Supplier No. HY10331A50MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Regorafenib monohydrate is the monohydrate form of regorafenib, a multi-targeted receptor tyrosine kinase inhibitor used as a research reagent and analytical standard. It exhibits potent inhibition of VEGFR, PDGFR, KIT, RET, and RAF kinases and is used in preclinical assays to study antitumor and antiangiogenic activity.

  • High purity (≈99.9%) suitable for analytical work.
  • Monohydrate form with molecular weight 500.8 g/mol.
  • Useful as an analytical standard and research reagent in kinase assays.
  • Available in small, quantified laboratory packages for preclinical studies.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.